A Phase 2 interventional study of Regorafenib, (Stivarga, BAY73-4506) and Nivolumab (Opdivo) in Solid Tumors, sponsored by Bayer. Completed at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 5th largest by enrollment, is one of 2 that started in 2021, is one of 27 in phase 2, and was the 32nd registered.
2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 574 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
Mayo Clinic · Sites in United States
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 32 · Phase 3 7
First in 2014; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 48 across 1,654 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 44 across the 46 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 46 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 6 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
5 of the studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03576417Phase 3Groupe Oncologie Radiotherapie Tete et CouA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck | 2027-08 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT04831320Washington University School of MedicineNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | 2027-06-30 |
| NCT03406247Gustave Roussy, Cancer Campus, Grand ParisAdjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
In this trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors. These include tumors in the head and neck, the esophagus, the pancreas, the brain, and the biliary tract. The biliary tract includes gall bladder and bile ducts.
The trial will include about 200 participants who are at least 18 years old. All of the participants will take 90 mg of regorafenib as a tablet by mouth. The dose of regorafenib can be adjusted up to 120 mg or down to 60 mg by the doctor based on how well a participant tolerates treatment. All of the participants will receive 480 milligrams (mg) of nivolumab through a needle put into a vein (IV infusion).
The participants will take treatments in 4-week periods called cycles. They will take regorafenib once a day for 3 weeks, then stop for 1 week. In each cycle, the participants will receive nivolumab one time. These 4-week cycles will be repeated throughout the trial. The participants can take nivolumab and regorafenib until their cancer gets worse, until they have medical problems, or until they leave the trial. The longest nivolumab can be given is up to 2 years.
During the trial, the doctors will take pictures of the participants' tumors using CT or MRI and will take blood and urine samples. The doctors will also do physical examinations and check the participants' heart health using an electrocardiogram (ECG). They will ask questions about how the participants are feeling and if they have any medical problems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate hematologic and organ function as assessed by the following laboratory tests performed within 7 d before start of study treatment including:
Exclusion Criteria:
ESCC:
GBM/AA
History of cardiac disorders as defined by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Parallel-cohort in adult participants with selected recurrent or metastatic tumors (HNSCC, ESCC, PDAC, BTC, and GBM/AA) who have been previously treated with one or more systemic therapy for the selected tumor indication.
Drug: Regorafenib, (Stivarga, BAY73-4506) · Drug: Nivolumab (Opdivo)
Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off). If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets).
480 mg administered on Day 1 of each treatment cycle.
Overall Response Rate (ORR)
Tumor response was evaluated as ORR per RECIST 1.1 by local assessments for all tumor types, except for GBM/AA, where ORR per RANO by local assessment was used. ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR). Participants for whom best overall tumor response was not CR or PR, as well as participants without any post-baseline tumor assessment were considered non-responders. Descriptive statistics were done, no inferential statistical analyses were performed.
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Duration of Response (DOR)
Defined as the time (in days) from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. participants with a CR or PR.
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Disease Control Rate (DCR)
CR = Complete response; PR = Partial response; SD = Stable disease
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Progression Free Survival (PFS)
PFS was defined as the time (in days) from the start of study intervention to the date of first objectively documented progressive disease (PD) or death from any cause (if no progression was documented).
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
6 Months PFS
6 Months PFS rate
Time frame: Up to last participant follow 6 months (approximately 22 months)
Overall Survival (OS)
OS was defined as the time (in days) from the start of study intervention to the date of death due to any cause.
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
1 Year OS
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 month]
Number of Participants With Adverse Events
AEs were considered to be treatment-emergent (TEAEs) if they started or worsened after the start of first study drug administration until 30 days after regorafenib treatment discontinuation or 100 days after the last dose of nivolumab, whatever occurred later.
Time frame: Up to the last participant has been followed for approximately 10 months, summed up to approximately 26 months
The study was conducted at 34 study centers in 8 countries/regions from 03 February 2021 (first patient first visit) to 29 March 2024 (last patient last visit)
| Milestone | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Started | 30 | 20 | 30 | 20 | 45 | 30 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 30 | 20 | 30 | 20 | 45 | 30 |
| Withdrew: Adverse event | 3 | 2 | 4 | 2 | 3 | 0 |
| Withdrew: Death | 3 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Participant decision | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 19 | 17 | 20 | 18 | 36 | 30 |
| Withdrew: Completed max. allowed treatment. a max. of 24 infusions of nivolumab were allowed for participants | 2 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Patient continued in rollover study for regorafenib | 1 | 0 | 4 | 0 | 0 | 0 |
Tumor response was evaluated as ORR per RECIST 1.1 by local assessments for all tumor types, except for GBM/AA, where ORR per RANO by local assessment was used. ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR). Participants for whom best overall tumor response was not CR or PR, as well as participants without any post-baseline tumor assessment were considered non-responders. Descriptive statistics were done, no inferential statistical analyses were performed.
| Participants | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 6 | 1 | 15 | 0 | 2 | 1 |
Defined as the time (in days) from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. participants with a CR or PR.
| Days | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Duration of Response (DOR) | NA (654 to NA) | NA (NA to NA) | 420 (112 to 617) | — | 432 (112 to NA) | 140 (NA to NA) |
CR = Complete response; PR = Partial response; SD = Stable disease
| Participants | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) | 16 | 13 | 22 | 7 | 24 | 10 |
PFS was defined as the time (in days) from the start of study intervention to the date of first objectively documented progressive disease (PD) or death from any cause (if no progression was documented).
| Days | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 79 (50 to 227) | 105 (52 to 115) | 259 (110 to 472) | 53 (48 to 111) | 98 (55 to 112) | 55 (52 to 84) |
6 Months PFS rate
| Proportion of participants | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| 6 Months PFS | 0.455 (0.337 to 0.573) | 0.263 (0.134 to 0.393) | 0.533 (0.417 to 0.650) | 0.050 (0.000 to 0.112) | 0.148 (0.077 to 0.218) | 0.167 (0.079 to 0.254) |
OS was defined as the time (in days) from the start of study intervention to the date of death due to any cause.
| Days | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Overall Survival (OS) | 358 (198 to 418) | 355 (126 to 614) | 627 (431 to 865) | 259 (134 to 311) | 246 (176 to 386) | 245 (127 to 377) |
| Proportion of participants | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| 1 Year OS | 0.415 (0.298 to 0.532) | 0.444 (0.294 to 0.595) | 0.764 (0.664 to 0.864) | 0.281 (0.145 to 0.418) | 0.422 (0.323 to 0.521) | 0.337 (0.223 to 0.451) |
AEs were considered to be treatment-emergent (TEAEs) if they started or worsened after the start of first study drug administration until 30 days after regorafenib treatment discontinuation or 100 days after the last dose of nivolumab, whatever occurred later.
| Participants | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Any AE | 30 | 20 | 30 | 20 | 45 | 30 |
| Worst grade: Grade 1 | 1 | 0 | 2 | 0 | 1 | 0 |
| Worst grade: Grade 2 | 4 | 1 | 6 | 2 | 9 | 8 |
| Worst grade: Grade 3 | 16 | 16 | 18 | 11 | 23 | 11 |
| Worst grade: Grade 4 | 6 | 2 | 2 | 2 | 1 | 2 |
| Worst grade: Grade 5 (death) | 3 | 1 | 2 | 5 | 11 | 9 |
Collected over Up to the last participant has been followed for approximately 10 months, summed up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HNSCC (IO Naive) | 22/30 (73.3%) | 22/30 (73.3%) | 30/30 (100%) |
| HNSCC (IO Treated) | 17/20 (85%) | 15/20 (75%) | 20/20 (100%) |
| ESCC | 20/30 (66.7%) | 19/30 (63.3%) | 30/30 (100%) |
| PDAC | 17/20 (85%) | 13/20 (65%) | 20/20 (100%) |
| Biliary Tract Cancer (BTC) | 36/45 (80%) | 28/45 (62.2%) | 45/45 (100%) |
| GBM/AA | 27/30 (90%) | 13/30 (43.3%) | 29/30 (96.7%) |
| Event | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| General physical health deteriorationGeneral disorders | 2/30 | 1/20 | 0/30 | 1/20 | 7/45 | 9/30 |
| PneumoniaInfections and infestations | 4/30 | 4/20 | 4/30 | 0/20 | 1/45 | 0/30 |
| CholangitisHepatobiliary disorders | 0/30 | 0/20 | 0/30 | 0/20 | 5/45 | 0/30 |
| Bile duct stenosisHepatobiliary disorders | 0/30 | 0/20 | 0/30 | 2/20 | 0/45 | 0/30 |
| DysphagiaGastrointestinal disorders | 2/30 | 1/20 | 1/30 | 0/20 | 0/45 | 0/30 |
| PancreatitisGastrointestinal disorders | 1/30 | 0/20 | 2/30 | 0/20 | 0/45 | 0/30 |
| Septic shockInfections and infestations | 0/30 | 0/20 | 2/30 | 0/20 | 0/45 | 0/30 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/30 | 0/20 | 0/30 | 0/20 | 0/45 | 0/30 |
| Decreased appetiteMetabolism and nutrition disorders | 2/30 | 1/20 | 1/30 | 0/20 | 0/45 | 0/30 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/30 | 1/20 | 2/30 | 0/20 | 0/45 | 0/30 |
| Event | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA |
|---|---|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 8/30 | 9/20 | 22/30 | 5/20 | 15/45 | 8/30 |
| RashSkin and subcutaneous tissue disorders | 6/30 | 2/20 | 14/30 | 8/20 | 10/45 | 5/30 |
| Decreased appetiteMetabolism and nutrition disorders | 8/30 | 9/20 | 11/30 | 7/20 | 14/45 | 6/30 |
| FatigueGeneral disorders | 4/30 | 7/20 | 9/30 | 8/20 | 19/45 | 5/30 |
| ConstipationGastrointestinal disorders | 7/30 | 8/20 | 7/30 | 7/20 | 15/45 | 11/30 |
| PyrexiaGeneral disorders | 6/30 | 6/20 | 12/30 | 7/20 | 17/45 | 5/30 |
| DiarrhoeaGastrointestinal disorders | 7/30 | 3/20 | 11/30 | 3/20 | 17/45 | 6/30 |
| Abdominal painGastrointestinal disorders | 0/30 | 1/20 | 4/30 | 7/20 | 11/45 | 4/30 |
| NauseaGastrointestinal disorders | 3/30 | 2/20 | 5/30 | 7/20 | 14/45 | 4/30 |
| HypertensionVascular disorders | 5/30 | 7/20 | 4/30 | 6/20 | 11/45 | 8/30 |
Full analysis set (FAS): all participants who received study treatment were included in the full analysis set
| Age, Customized(Participants) | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA | Total |
|---|---|---|---|---|---|---|---|
| <65 years | 16 | 10 | 17 | 13 | 17 | 22 | 95 |
| 65-<75 years | 12 | 4 | 11 | 7 | 22 | 7 | 63 |
| 75-<85 years | 2 | 6 | 2 | 0 | 6 | 1 | 17 |
| Sex: Female, Male(Participants) | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 6 | 3 | 11 | 20 | 10 | 55 |
| Male | 25 | 14 | 27 | 9 | 25 | 20 | 120 |
| Race (NIH/OMB)(Participants) | HNSCC (IO Naive) | HNSCC (IO Treated) | ESCC | PDAC | Biliary Tract Cancer (BTC) | GBM/AA | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 15 | 11 | 21 | 5 | 11 | 2 | 65 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 6 | 6 | 7 | 13 | 27 | 26 | 85 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 3 | 2 | 2 | 6 | 2 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Feb 2021 to primary completion in Mar 2023, 25 months.
Results were first posted in Jul 2024, 1 year 4 months after primary completion.
Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 25 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Regorafenib · Nivolumab
Squamous Cell Carcinoma of Head and Neck →